Breast medical oncologist and researcher @UCLA | Views my own
Los Angeles, CA
- Tweets 460
- Following 417
- Followers 509
- Likes 1,291
Alexis LeVee, MD retweeted
Adding carboplatin to neoadjuvant chemotherapy improves pathologic response and event-free survival in early-stage TNBC, while immune signatures provide additional prognostic insights @JCOOA_ASCO @hoperugo
ascopubs.org/doi/pdf/10.1200…
6
18
1,210
Alexis LeVee, MD retweeted
We encourage all eligible @ASCO members to make their voice heard by voting in the ASCO Election. We are proud to support MOASC President Dr. Sumanta Pal @montypal and MOASC Board Member Dr. Mina Sedrak @minasedrakmd as candidates for leadership roles within ASCO. Vote today at asco.org/election and help shape the future of oncology. #ASCOElection #OncologyLeadership
7
15
1,282
Vote for @minasedrakmd for ASCO Nominating Committee! Mina has been such an incredible mentor to me since fellowship and has made such an impact on the oncology community through his mentorship, teaching, research, and advocacy work.
Vote here: asco.org/about-asco/asco-ove…
Voting for ASCO Election closes Mon, Dec 8 @ 3PM ET! I am honored to be running as one of the candidates for the Nominating Committee. Visit asco.org/election to learn more and vote!
7
253
Vote for @montypal for ASCO Board! I’ve been so lucky to have Monty as a mentor whose dedication and support for junior faculty and trainees is truly remarkable. He is an incredible person with extensive ASCO leadership experience - he is an outstanding candidate for the Board.
Vote here: asco.org/about-asco/asco-ove…
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
5
23
1,027
Alexis LeVee, MD retweeted
First prospective switch trial of Top1 ADC post Top1 ADC in MBC.
0-8% ORR
Switching target with same payload simply does not work.
Resistance is in payload.
Let’s stop talking about “sequencing”. It simply does not work. We need new payloads.
#MBC #BCSM #ESMO26
3
24
82
3,374
Alexis LeVee, MD retweeted
OptiTROP-Breast01
Sac-TMT vs chemo in mTNBC (≥2chemo/≥1 in MBC)
OS: 14.7 vs 9.9 mo, HR 0.60, p=0.0004
@OncoAlert #ESMO26
2
24
53
3,524
Alexis LeVee, MD retweeted
TROPION-Breast02 CNS fabulously presented by @RebeccaDSing
n=61 with baseline brain mets
n=35 on Dato-DXd arm (16 had prior treatment for brain mets)
PFS HR 0.37, OS HR 0.55
iORR: 62.5% vs 37.5%
@OncoAlert #ESMO26
22
35
1,755
Had a wonderful time at the Sharsheret 5K Walk supporting breast and ovarian cancer awareness! Grateful to be part of this community dedicated to raising awareness and support for those affected by these cancers at the end of breast cancer awareness month #Sharsheret #breastcancer #ovariancancer #bcsm @UCLAHealthJCCC
2
16
595
Alexis LeVee, MD retweeted
At #ESMO26 proffered paper session 1️⃣ on #breastcancer
Final results of B-42 (15-y analysis)
Extended ET (10 vs. 5 years) confirms a modest but significant improvement in DFS, BCFI and DR
Larger benefit in DR for node+
No OS difference
No ⬆️ osteoporotic fx
@OncoAlert
10
12
572
Alexis LeVee, MD retweeted
At #ESMO26 proffered paper session 1️⃣ on #breastcancer
Trastuzumab rezetecan in HER2-low aBC vs CT of physician’s choice ⬆️ PFS in chemo-naive and overall patients
Consistent benefit according to HR status
Simultaneous publication on @JAMA_current
@OncoAlert
5
16
476
Alexis LeVee, MD retweeted
#PANKUBreast01
Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC
🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41
🔹 ORR: 20% vs 40%
🔹 DoR: 4.2 vs. 6.9 mo
🔹 ILD: only 1.1% & all grade 1/2
#ESMO26 #ESMOAmbassadors
10
22
2,269
Alexis LeVee, MD retweeted
#ESMO26
Today, we’ll probably spend most of our time discussing NATALEE!
At 6 years, OS: 91.9% vs 89.7% (HR 0.81; nominal p=0.019).
BCSS benefit is also encouraging (HR 0.71).
Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors…
The 6-year OS rates in NATALEE were 91.86% vs 89.73%: an absolute gain of 2.1 percentage points (HR 0.809; 95% CI 0.661–0.989; nominal one-sided p=0.019).
The absolute 7-year OS gain in monarchE was 1.8 percentage points (HR 0.842; p=0.027). I do not think these gains should be dismissed as “only 2%.”
In the EBCTCG analysis, adding taxanes to anthracycline-based chemotherapy—an approach we have accepted as standard for years—provided an absolute 5-year OS gain of approximately 1.9 percentage points. The populations and follow-up periods differ, so we cannot directly compare treatment efficacy. However, the standards we use to judge a few percentage points of survival benefit should be consistent.
Moreover, 95.4% of patients in monarchE had already received chemotherapy. This survival gain represents an additional benefit on top of chemotherapy and endocrine therapy.
Patient selection, toxicity, treatment duration, and cost certainly deserve discussion. However, the survival benefit of adjuvant CDK4/6 inhibitors in appropriately selected patients should not be underestimated.
3
15
35
5,330
Alexis LeVee, MD retweeted
#ESMO26
Optimal duration of adjuvant endocrine therapy: 5, 7–8, or 10 years?
From Dr. Fumikata Hara’s excellent discussion👇
3
55
124
7,393
Alexis LeVee, MD retweeted
David Page does an outstanding job presenting the correlatives from our neoHIP IIT looking at the addition of #immunotherapy to preop THP in HER2+ dz #ESMO26
4
6
606
Alexis LeVee, MD retweeted
“Chemo brain” is one of the most common things my patients ask me about. We still have no proven drug to treat it.
In our small phase II trial, breast cancer survivors with cognitive complaints took oxaloacetate for 8 weeks. Every participant who completed the study reported improvement in cognition, along with less fatigue and better physical function.
It’s an early signal, not an answer. A randomized, placebo-controlled trial is the next step.
Led by Dr. Patti Ganz, with thanks to @BCRFcure. Out now in @JCOOA_ASCO.
doi.org/10.1200/OA-26-00063 #bcsm
2
14
31
1,543
Alexis LeVee, MD retweeted
In @Annals_Oncology, results from a new phase 3 trial (HELEN Trio011 🇨🇳) showing improved pCR with PD1-blockade added to carbo/taxotere for TNBC. Together with NeoPACT, these results offer an alternative, anthracycline-sparing neoadjuvant regimen for TNBC. annalsofoncology.org/article…
1
20
70
7,769
Alexis LeVee, MD retweeted
This is an important article. A US-based, randomized study shows no benefit to focal ablation of asymptomatic metastatic disease in advanced breast cancer. Such approaches should not be considered standard of care.
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. bit.ly/3VGspka
#BreastCancer #bcsm
2
17
39
4,693
Alexis LeVee, MD retweeted
Based off HER2CLIMB-05, Tucatinib is now @FDA ✅ as maintenance for HER2+ mBC, PhIII, THP —> HP +/-Tucatinib
- Improved PFS in all subsets
- mPFS: 24.9mos vs. 16.3mos (HR: 0.64)
- ⬆️ AEs with Tucatinib (LFTs & diarrhea)
#BreastCancer #bcsm #OncTwitter
4
21
39
8,194